Oppenheimer Asset Management Inc. Increases Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Oppenheimer Asset Management Inc. increased its holdings in Repligen Co. (NASDAQ:RGEN) by 7.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,985 shares of the biotechnology company’s stock after buying an additional 1,411 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Repligen were worth $3,123,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in RGEN. Andra AP fonden purchased a new stake in shares of Repligen in the second quarter valued at about $25,000. International Assets Investment Management LLC purchased a new stake in Repligen in the 2nd quarter valued at approximately $33,000. UMB Bank n.a. lifted its stake in Repligen by 138.3% in the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 130 shares in the last quarter. Lazard Asset Management LLC increased its position in Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after buying an additional 136 shares in the last quarter. Finally, Blue Trust Inc. raised its holdings in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 127 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. This represents a 13.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.20% of the stock is owned by company insiders.

Repligen Price Performance

RGEN stock opened at $124.73 on Friday. The stock has a 50-day moving average price of $141.54 and a two-hundred day moving average price of $144.77. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $211.13. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The company has a market cap of $6.99 billion, a PE ratio of -337.10, a price-to-earnings-growth ratio of 4.36 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The firm had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. During the same quarter in the previous year, the business earned $0.23 earnings per share. The firm’s quarterly revenue was up 9.7% compared to the same quarter last year. As a group, research analysts predict that Repligen Co. will post 1.44 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on RGEN shares. Wells Fargo & Company started coverage on Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target for the company. Stephens reissued an “overweight” rating and issued a $170.00 price target on shares of Repligen in a report on Tuesday, July 30th. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Wolfe Research initiated coverage on Repligen in a research note on Thursday. They issued a “peer perform” rating for the company. Finally, Benchmark reiterated a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $190.25.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.